期刊文献+

RON及Claudin-4在人膀胱移行细胞癌中的表达及临床意义 被引量:2

Expression and clinic significance of RON and claudin-4 in bladder transitional cell carcinoma
下载PDF
导出
摘要 目的研究RON(recepteur d’origine naetais)及Claudin-4在人膀胱移行细胞癌(bladder transitional cell car-cinoma,TCCB)中的表达及临床意义,探讨两者在肿瘤中的作用。方法收集人正常膀胱移行上皮组织标本16例,膀胱移行细胞癌标本36例,按照病理分级、临床分期、性别、年龄、单发与多发、初发与复发进行分组,分别用Western blot和RT-PCR检测RON、Claudin-4蛋白和mRNA的表达,分析两者与TCCB的病理分级、临床分期、性别、年龄、单发与多发、初发与复发间的关系。结果①TCCB组中的RON表达水平明显高于正常膀胱移行上皮组织(P=0.000),TCCB组低级别与高级别、非肌层浸润(T1)与肌层浸润(T2~4)间表达差异有统计学意义(P=0.003,P=0.000),而在年龄、初发与复发、单发与多发组间表达差异无统计学意义(P>0.05)。②TCCB组中的Claudin-4表达水平明显高于正常膀胱黏膜组织(P=0.003),TCCB组T1与T2~4间表达差异有统计学意义(P=0.018),而在低级别与高级别、年龄、初发与复发、单发与多发组间表达差异无统计学意义(P>0.05)。③TCCB组RON与Claudin-4蛋白及基因表达水平均呈增高趋势,且两者呈正相关(r=0.560,P<0.05)。结论 TCCB组中RON与Claudin-4蛋白及基因表达上调提示两者在TCCB的发展和浸润中起促进作用,且RON与Claudin-4在TCCB中呈正相关。 Objective To determine the expression and clinic significance of recepteur d'origine naetais(RON) and claudin-4 in bladder transitional cell carcinoma(TCCB) and investigate their possible role in progression and invasion of TCCB.Methods A total of 36 patients with pathological identified TCCB undergoing radical cystectomy in our department during March 2010 to May 2011 were recruited in this study.Their clinical data including pathological grades,clinical stages,single and multiple foci,primary and recurrence tumor were collected.The expression of RON and claudin-4 in the tissue samples of 16 normal bladder tissues and these 36 TCCB were tested by Western blotting and reverse transcription polymerase chain reaction(RT-PCR) at protein and mRNA levels,respectively.The relationships between RON and claudin-4 with pathological grades,clinical stages,sex,age,single and multiple foci,primary and recurrence tumor were also analyzed.Results The expression of RON in TCCB was significantly higher than in normal bladder tissues(P=0.000),and significant differences were found in low-grade and high grade differentiation,and in non-muscle invasion and muscle-invasive tumors(P=0.003,P=0.000),but not in different sex,age,primary and recurrence tumor,and single and multiple foci(P0.05).The expression of claudin-4 in TCCB was significantly higher than in normal bladder tissues(P=0.003),and significant difference was found between non-muscle invasion and muscle-invasive tumors(P=0.018),but not in low-grade and high grade differentiation,sex,age,primary and recurrence tumor,and single and multiple foci(P0.05).Both the protein and mRNA levels of RON and claudin-4 were higher in TCCB than those in normal bladder tissues,and were positively correlated(r=0.560,P0.05).Conclusion RON and Claudin-4 are up-regulated and positively correlated in TCCB,indicating that they may exert a positive regulatory effect on the progression and invasion.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2012年第4期298-302,共5页 Journal of Third Military Medical University
关键词 膀胱移行细胞癌 RON CLAUDIN-4 逆转录聚合酶链反应 印迹法 蛋白质 bladder transitional cell carcinoma recepteur d'origine naetais claudin-4 reverse transcriptase polymerase chain reaction blotting western
  • 相关文献

参考文献1

二级参考文献74

  • 1Ciardiello F, Tortora C. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
  • 2Zwick E, Bange J, UIIrich A. Receptor tyrosine kinase signaling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8: 161- 73.
  • 3Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem 2009; 9: 221-25.
  • 4Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010; 16: 37-45.
  • 5Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Bio12007; 19: 117-23.
  • 6Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 2010; 70: 3857-60.
  • 7Robertson SC, Tynan JA, Donoghue DJ. RTK mutations and human syndromes when good receptors turn bad. Trends Genet 2000; 16: 265 - 71.
  • 8Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998; 17: 1343-52.
  • 9Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411: 355-65.
  • 10Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Onco12006; 3: 448-57.

共引文献9

同被引文献18

  • 1Christen L Walters Haygood,Rebecca C Arend,J Michael Straughn,Donald J Buchsbaum.Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?[J].World Journal of Stem Cells,2014,6(4):441-447. 被引量:7
  • 2Diéras V,Harbeck N,Budd GT,et al.Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer:An Integrated Safety Analysis[J].J Clin Oncol,2014,32(25):2750-2757.
  • 3Samuel TA,Stone E.Is the era of HER2over?Pertuzumab in the neoadjuvant treatment of early HER2-positive breast cancer[J].J Community Support Oncol,2014,12(3):78-81.
  • 4Wheler JJ,Moulder SL,Naing A,et al.Anastrozole and everolimus in advanced gynecologic and breast malignancies:activity and molecular alterations in the PI3K/AKT/mTOR pathway[J].Oncotarget,5(10):3029-3038.
  • 5Kotler BM,Kerstetter JE,Insogna KL.Claudins,dietary milk proteins,and intestinal barrier regulation[J].Nutr Rev,2013,71(1):60-65.
  • 6Jo VY,Cibas ES,Pinkus GS.Claudin-4immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology[J].Cancer Cytopathol,2014,122(4):299-306.
  • 7Lee KW,Lee NK,Kim JH,et al.Twist1causes the transcriptional repression of claudin-4with prognostic significance in esophageal cancer[J].Biochem Biophys Res Commun,2012,423(3):454-460.
  • 8Ersoz S,Mungan S,Cobanoglu U,et al.Prognostic importance of Claudin-1and Claudin-4expression in colon carcinomas[J].Pathol Res Pract,2011,207(5):285-289.
  • 9Li C,Yang W,Zhang J,et al.SREBP-1has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma[J].Int J Mol Sci,2014,15(5):7124-7138.
  • 10Trotter K,Schneider SM,Turner BS.Group appointments in a breast cancer survivorship clinic[J].J Adv Pract Oncol,2013,4(6):423-431.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部